Advertisement

Topics

Kyowa Hakko Kirin Co. Ltd. Company Profile

21:53 EDT 16th October 2018 | BioPortfolio


News Articles [106 Associated News Articles listed on BioPortfolio]

Kyowa Hakko Kirin Announces FDA Notification of PDUFA Action Date Extension for Mogamulizumab

Tokyo, Japan, May 30, 2018 –Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151 President and COO: Masashi Miyamoto, “Kyowa Hakko Kirin”) announced today that it has been notified that the U.S. Food and Dr...

Crysvita Meets Primary Endpoint in Phase 3 Trial in Children with X-Linked Hypophosphatemia

NOVATO, Calif. and TOKYO and LONDON, May 17, 2018 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products fo...

Kyowa Hakko Kirin Co., Ltd. Strategy, SWOT and Corporate Finance Report [Report Updated: 20062018] Prices from USD $175

Kyowa Hakko Kirin Co., Ltd. Strategy, SWOT and Corporate Finance ReportSummaryKyowa Hakko Kirin Co., Ltd. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and i...

FDA Approves Crysvita, The First Therapy for X-Linked Hypophosphatemia, A Rare Inherited Form of Rickets

NOVATO, Calif. and TOKYO and LONDON, April 17, 2018 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel produ...

Kyowa Kirin gibt positive Stellungnahme des CHMP zu Mogamulizumab zur Behandlung von Mycosis fungoides und Sézary-Syndrom bekannt

Tokio (ots/PRNewswire) - Mogamulizumab wäre nach Zulassung der erste biologische Wirkstoff gegen CCR4 für Patienten in Europa. Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin), hat heute bekanntgegeben, ....

FDA Approves Kyowa Kirin’s Poteligeo for Treatment of Two Rare Types of Non-Hodgkin Lymphoma

TOKYO, Aug. 8, 2018 /PRNewswire/ — Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for Poteligeo® (mogamulizumab...

Lancet publishes PhIII data on Kyowa Hakko’s Poteligeo

The Lancet has published data from Kyowa Hakko Kirin Co’s successful Phase III trial of immunotherapy Poteligeo underpinning its recent approval in the US to treat in patients with cutaneous T-c...

Kyowa Kirin reports positive results from MAVORIC study

Japan-based Kyowa Hakko Kirin has reported positive results from the Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL (MAVORIC) study after...Read More... The post Kyowa Kirin reports positi...

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Burosumab: First Global Approval.

Burosumab (Crysvita; Kyowa Hakko Kirin Co., Ltd. and Ultragenyx Pharmaceutical Inc.) is a fully human monoclonal antibody directed at fibroblast growth factor 23 (FGF23). Excessive FGF23 production ha...

Clinical Trials [0 Results]

None

Companies [17 Associated Companies listed on BioPortfolio]

Kyowa Hakko Kirin Co. Ltd.

Kyowa Hakko Kirin Co., Ltd.

Kyowa Pharmaceutical, Inc

From its foundation in 1949, Kyowa Hakko has been a global leader in the pharmaceutical industry. Today, Kyowa's expertise extends to the United States through Kyowa Pharmaceutical, Inc. headquartered...

Kyowa Hakko

Kyowa Hakko USA

More Information about "Kyowa Hakko Kirin Co. Ltd." on BioPortfolio

We have published hundreds of Kyowa Hakko Kirin Co. Ltd. news stories on BioPortfolio along with dozens of Kyowa Hakko Kirin Co. Ltd. Clinical Trials and PubMed Articles about Kyowa Hakko Kirin Co. Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kyowa Hakko Kirin Co. Ltd. Companies in our database. You can also find out about relevant Kyowa Hakko Kirin Co. Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record